Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase (n 2) and accelerated phase (n 2) CML patients received dasatinib at starting dose of 100 and 140 mg once daily, res...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Serpa, Mariana, Sanabani, Sabri S., Bendit, Israel, Seguro, Fernanda, Xavier, Flávia, Barroso, Cláudia Bitti, Conchon, Monika, Dorlhiac-Llacer, Pedro Enrique
Médium: Artigo
Jazyk:Inglês
Vydáno: Libertas Academica 2010
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018898/
https://ncbi.nlm.nih.gov/pubmed/21234296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6413
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky